Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Lung Cancer Clinical Trial

Official title:

A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02466568
• Other study ID #: MCC-18147
• Secondary ID: 1504-1392
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: July 2018
• Est. completion date: July 2020

Study information

• Verified date: September 2019
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out what effects (good and bad) a tumor vaccine (GM.CD40L) used in combination with Nivolumab will have on participants and their cancer. Another purpose of the study is to find out the maximum tolerated dose of nivolumab in combination with GM.CD40L vaccine. Investigators also want to find out if the combination of GM.CD40L and nivolumab can boost the immune system of participants like you, and how their immune system reacts, both before and after the treatment.

Description:

This study has two parts and participants may be involved in either Phase I part or Phase II.

Phase I: Investigators plan to enroll participants in cohorts of 6 and monitor side effects over a 21 day period to determine the maximum tolerated dose (MTD) of nivolumab, which will be given in combination with GM.CD40L. This is being done since this study involves a combination of treatments that have not been studied in humans before and to find the best dose for the Phase II part of the study.

Phase II: Investigators plan to compare any clinical benefit in the participants who receive the combination of GM.CD40L vaccine with nivolumab, to participants that receive only nivolumab.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2020
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic or cytologic diagnosis of advanced/metastatic adenocarcinoma of the lung

• Eastern Cooperative Oncology Group (ECOG) performance status of 0/1

• Chemotherapy naïve or have completed adjuvant chemotherapy for non-small cell lung cancer (NSCLC) >6 months prior

• Adequate bone marrow, renal and hepatic function

• Must have measurable metastatic disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria

• Mandatory archival tissue or willingness to undergo a fresh biopsy

• Life expectancy of greater than 6 months

Exclusion Criteria:

• Symptomatic brain metastasis or uncontrolled central nervous system (CNS) metastasis

• Pregnancy or breast feeding

• Serious uncontrolled medical disorder or active infection that would impair the participant's ability to receive study treatment

• Prior use of a PD1 or PDL1 inhibitor

• Concurrent use of other anticancer approved or investigational agents is not allowed

• Autoimmune disorders

• Prior malignancy in past 2 years

• Systemic steroids at doses greater than 10 mg/day of prednisone or the equivalent

• Any other pre-existing immunodeficiency condition (including known HIV infection)

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of Lung
• Adenocarcinoma of the Lung
• Lung Cancer

Intervention

Drug:
• Nivolumab
Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.

Biological:
• GM.CD40L Vaccine
GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Recommended Phase II Dose	The recommended Phase II dose will be defined as the highest dose level of GMCD40L vaccine in combination with nivolumab that induced dose limiting toxicity (DLT) in fewer than 33% of patients.	Up to 2 months
Primary	Phase II: Objective Response Rate (ORR)	Objective tumor response per treatment arm. ORR: Complete Response (CR) = disappearance of all target lesions + Partial Response (PR) = 30% decrease in the sum of the longest diameter of target lesions.	Up to 2 years
Secondary	Phase II: Overall Survival (OS)	OS per treatment arm. Overall survival is defined as the time from randomization until death from any cause.	Up to 2 years
Secondary	Phase II: Progression-free Survival (PFS)	PFS per treatment arm. Progressive Disease (PD): = 20% increase in the sum of the longest diameter of target lesions.	Up to 2 years

External Links

•   Moffitt Cancer Center Clinical Trials website